Navigation Links
Par Pharmaceutical Receives Final Approval to Market Generic Marinol(R) CIII (Dronabinol) Capsules
Date:6/30/2008

Par to Begin Shipping Dronabinol Soft Gel Capsules Immediately

WOODCLIFF LAKE, N.J., June 30 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for dronabinol, a generic version of Solvay Pharmaceutical's Marinol(R), a CIII controlled substance. This product is approved to treat nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments and is available in 2.5mg, 5 mg and 10 mg strengths. Annual U.S. sales of Marinol are approximately $190 million, according to IMS Health data. Par will begin shipping all strengths of dronabinol soft gel capsules to the trade immediately.

Under the terms of a license and distribution agreement with SVC Pharma LP, an affiliate of Rhodes Technologies, Par has the right to market, sell and distribute dronabinol in the U.S. Par and SVC Pharma LP will share profits equally from the sales of the product.

Important information about dronabinol soft gel capsules

Dronabinol is contraindicated in any patient who has a history of hypersensitivity to any cannabinoid, sesame oil or any ingredients in dronabinol capsules. Warn patients not to drive, operate machinery, or engage in hazardous activity until they establish they can tolerate dronabinol and perform such tasks.

Dronabinol should be used with caution in patients with a history of seizure disorder; patients with cardiac disorders; patients with a history of substance abuse (including alcohol abuse or dependence); patients with mania, depression, or schizophrenia (along with careful psy
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 Intrinsic Imaging, ... certified, GAMP® 5 compliant imaging core lab, announced ... Phase II clinical trial to assess a new ... this trial, Intrinsic Imaging will provide comprehensive imaging ... protocol and charter development, site qualification, site training ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and provides users ... said Mark Tess, PhD, Mycotoxin Product Manager for Charm Sciences. ... USDA-GIPSA inspection agencies that have a need to detect aflatoxin ... a matter of minutes with nothing but our equipment and ... grain before accepting it, but they no longer have to ...
(Date:8/28/2014)... Grove, PA (PRWEB) August 28, 2014 ... and create a culture that will allow individuals to ... are becoming increasingly important for employers looking to compete ... science industries are embracing this trend, as the sector ... fabric of a company, which will have real results ...
(Date:8/28/2014)... PARK, Calif. , Aug. 28, 2014 /PRNewswire/ ... focused on developing novel mid- to late-stage cardiovascular ... $7.0 million in its first round of financing. ... Biomedical Investments and Hercules Bioventures with participation from ... entrepreneur and pharmaceutical executive, Dr. Larry Hsu ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... sponges, IUDs, diaphragms-- women have many options for planning their ... men want to help out? They have only two options ... crucial for dating but get old in long-term relationships. ... that nobody is every calling them "Daddy" before they are ...
... PPD, Inc. (Nasdaq:,PPDI) will release its third quarter 2007 ... The earnings release will be available,on the PPD Web ... On Wednesday, October 24, at 9 a.m. ET, ... to discuss financial results and the,overall business environment. A ...
... 28 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ... interim results from a U.K. Phase Ia/Ib ... with advanced or,metastatic cancers is scheduled to ... (NCRI) conference on October 2, 2007 in ...
Cached Biology Technology:Of mice and men: new male contraceptives successful in rodents and humans 2PPD Announces Third Quarter 2007 Earnings Release, Webcast and Conference Call 2Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 2Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 3Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 4
(Date:8/28/2014)... for delivering compounds that could positively impact ... may be possible, thanks to researchers in ... semi-soft vaginal suppository made from the seaweed-derived ... antiviral drug Tenofovir provides a woman-initiated, drug-delivery ... of sexually transmitted infections during unprotected heterosexual ...
(Date:8/28/2014)... August 28, 2014 Dyslexia, the most commonly ... a neurological reading disability that occurs when the ... don,t function normally. , The use of non-invasive ... activity is disrupted in dyslexia. However, most prior ... of brain regions, leaving a gap in our ...
(Date:8/28/2014)... the first person to alert the world to Global ... be captured and stored underground. He says that Carbon ... the best way to avoid global warming getting out ... (Columbia University, New York) made the call during his ... where 150 scientists are meeting to discuss Carbon Capture ...
Breaking Biology News(10 mins):Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Dyslexic readers have disrupted network connections in the brain 2Global warming pioneer calls for CO2 to be taken from atmosphere and stored underground 2
... and molecular biologists, chemists, physicists, material scientists, computational modelers ... the newly funded Center for Lignocellulose Structure and Formation, ... Penn State. The DOE plans to fund the ... Cosgrove, professor of biology, will direct the Center in ...
... human brain stores some kinds of memories for a ... at things, our gray matter also creates temporary memories ... seconds these visual memories exist. For decades, scientists have ... grow gradually more imprecise over the course of several ...
... A new longitudinal study of children,s personality traits ... differently in girls and boys. The study, by ... of Hawaii at Manoa, and Purdue University, appears ... Child Development . The researchers looked ...
Cached Biology News:Center to investigate plant cells for better biomass fuels 2Some short-term memories die suddenly, no fading 2Sugar, spice and puppy dog tails: Developing sex-typed personality traits and interests 2
15(S)-HEDE is produced from 11Z,14Z-eicosadienoic acid by 15-LO. 15(S)-HEDE is an inhibitor of RBL-1 cell 5-LO with an IC50 value of 26 µM....
Mouse monoclonal [HYB 232-02] to Protein S ( Abpromise for all tested applications). entrezGeneID: 5627 SwissProtID: P07225...
Simple operation and an easy-to-read LCD display characterize our Classic Light balances. * Taring range 0...1510 g...
... SLi 3 •3H 2 O Formula Weight: 881.42 ... pH 7.0): greater than or equal to 90% lambda max : 259 ... Spectral Ratios: A 232 /A 260 : 0.51 ... 280 /A 260 : 0.17 0.02 Storage: -20C ...
Biology Products: